Clene reports FY2025 net loss $26.2M; cash $5.2M; FDA type C meeting planned

Clene Inc.

Net loss of $26.2M ($2.65 per share) vs $39.4M ($5.67) in 2024.
R&D expenses $14.0M, down from $20.1M; G&A $9.2M, down from $13.3M.
Cash and equivalents $5.2M at Dec 31, 2025; expected runway to Q3 2026 after Jan 2026 offering.
Oversubscribed $28M registered direct offering; initial tranche $6M priced above market.
Type C FDA meeting before end of Mar 2026; NDA filing for CNM-Au8 in ALS by June 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.